Alexander Schmitz

Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Marianne Hutchings Hoffmann
  • ,
  • Tobias Wirenfeldt Klausen, Kliniske Institutter, Danmark
  • Martin Boegsted
  • Steffen Falgreen Larsen, Danmark
  • Alexander Schmitz
  • Eva Birgitte Leinoe
  • ,
  • Kjeld Schmiegelow, Danmark
  • Henrik Hasle
  • Olav Jonas Bergmann, Danmark
  • Suzette Sorensen, Danmark
  • Mette Nyegaard, Danmark
  • Karen Dybkaer, Danmark
  • Hans Erik Johnsen, Danmark
BACKGROUND: Individual cellular heterogeneity within the acute myeloid leukemia (AML) bone marrow samples can be observed by multi parametric flow cytometry analysis (MFC) indicating that immunophenotypic screening for leukemic blast subsets may have prognostic impact. MATERIAL AND METHODS: Samples from de novo AML patients of all cytogenetic risk groups were collected at diagnosis and subjected to MFC based on a four-color antibody panels against 33 CD membrane markers and retrospectively analyzed for the leukemia blast expression pattern and mean fluorescence intensity. Identification of the leukemic blast cells was based on right angle light scatter (SSC) and expression of CD45 and the cellular heterogeneity identified by the presence of at least two distinct subsets by any CD marker. RESULTS: Analysis of marrow samples from 86 patients with cytogenetic intermediate risk identified recurrent heterogeneous blast phenotypes for selected CD markers, three of which had prognostic impact with loss or gain of CD58, CD117, or CD14 expression. Multivariate Cox regression analysis of diagnostic variables identified poor prognostic factors: Age >55 years, presence of extramedullary disease, WHO performance score >2, a heterogeneous CD58, CD117, or CD14 expression on blast cells. Each variable added to a simple and clinical useful and MFC based prognostic score system associated to inferior survival in the intermediate risk group of AML patients. CONCLUSIONS: These observations support that leukemic blast heterogeneity detected by MFC has additional prognostic significance in de novo AML; however, the score system needs to be prospectively validated in future clinical trials before implementation. © 2012 International International Clinical Cytometry Society.
TidsskriftCytometry. Part B: Clinical Cytometry
Sider (fra-til)123-131
Antal sider9
StatusUdgivet - maj 2012

Se relationer på Aarhus Universitet Citationsformater

ID: 44363043